Sinopharm Group Co (X2S) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

X2S Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Sinopharm

Group Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

X2S Stock 12 Month Forecast

Average Price Target

€2.42

▲(39.89% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Sinopharm Group Co in the last 3 months. The average price target is €2.42 with a high forecast of €2.74 and a low forecast of €2.26. The average price target represents a 39.89% change from the last price of €1.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","0.75":"€0.75","1.5":"€1.5","2.25":"€2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.7420952,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4201487999999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.2647264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,1.7801611692307693,1.8603223384615384,1.9404835076923077,2.020644676923077,2.100805846153846,2.1809670153846152,2.2611281846153846,2.341289353846154,2.421450523076923,2.5016116923076925,2.581772861538462,2.6619340307692307,{"y":2.7420952,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,1.7553960615384614,1.810792123076923,1.8661881846153845,1.921584246153846,1.9769803076923076,2.0323763692307693,2.0877724307692307,2.143168492307692,2.1985645538461536,2.2539606153846155,2.309356676923077,2.3647527384615383,{"y":2.4201487999999998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,1.7434404923076923,1.7868809846153846,1.830321476923077,1.8737619692307692,1.9172024615384615,1.9606429538461536,2.004083446153846,2.0475239384615382,2.0909644307692306,2.134404923076923,2.177845415384615,2.2212859076923075,{"y":2.2647264,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.932,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.885,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.041,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.124,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.007,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.112,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.119,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.908,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.758,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.765,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.944,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€2.74

Average Price Target€2.42

Lowest Price Target€2.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Citi

Not Ranked

Citi

€2.51→€2.26

Buy

30.91%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from Citi

Unknown Analyst

CLSA

Not Ranked

CLSA

€2.34

Buy

35.40%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from CLSA

Unknown Analyst

CICC

Not Ranked

CICC

€2.74

Buy

58.50%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from CICC

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€2.33

Buy

34.76%

Upside

Reiterated

07/01/26

Citic Securities Remains a Buy on Sinopharm Group Co (SHTDF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

€2.55

Buy

47.59%

Upside

Reiterated

05/14/26

Sinopharm Group Co (SHTDF) Gets a Buy from Morgan Stanley

Unknown Analyst

UOB Kay Hian

Not Ranked

UOB Kay Hian

€1.89

Hold

9.09%

Upside

Reiterated

04/28/26

UOB Kay Hian Remains a Hold on Sinopharm Group Co (SHTDF)

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

€2.96

Buy

71.34%

Upside

Reiterated

04/04/26

Sinopharm Group Co (SHTDF) Gets a Buy from First Shanghai Securities

Unknown Analyst

Daiwa

Not Ranked

Daiwa

€2.33

Buy

34.76%

Upside

Reiterated

03/24/26

Daiwa Reaffirms Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

€2.5

Buy

44.58%

Upside

Reiterated

03/24/26

Huatai Securities Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

UBS

Not Ranked

UBS

€2.85

Buy

64.92%

Upside

Reiterated

03/23/26

UBS Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€2.2

Hold

27.25%

Upside

Reiterated

03/23/26

Sinopharm Group Co (SHTDF) Gets a Hold from Goldman Sachs

Unknown Analyst

HSBC

Not Ranked

HSBC

€2→€2.16

Sell

25.13%

Upside

Reiterated

11/10/25

HSBC Keeps Their Sell Rating on Sinopharm Group Co (SHTDF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Citi

Not Ranked

Citi

€2.51→€2.26

Buy

30.91%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from Citi

Unknown Analyst

CLSA

Not Ranked

CLSA

€2.34

Buy

35.40%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from CLSA

Unknown Analyst

CICC

Not Ranked

CICC

€2.74

Buy

58.50%

Upside

Reiterated

08/25/26

Sinopharm Group Co (SHTDF) Gets a Buy from CICC

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€2.33

Buy

34.76%

Upside

Reiterated

07/01/26

Citic Securities Remains a Buy on Sinopharm Group Co (SHTDF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

€2.55

Buy

47.59%

Upside

Reiterated

05/14/26

Sinopharm Group Co (SHTDF) Gets a Buy from Morgan Stanley

Unknown Analyst

UOB Kay Hian

Not Ranked

UOB Kay Hian

€1.89

Hold

9.09%

Upside

Reiterated

04/28/26

UOB Kay Hian Remains a Hold on Sinopharm Group Co (SHTDF)

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

€2.96

Buy

71.34%

Upside

Reiterated

04/04/26

Sinopharm Group Co (SHTDF) Gets a Buy from First Shanghai Securities

Unknown Analyst

Daiwa

Not Ranked

Daiwa

€2.33

Buy

34.76%

Upside

Reiterated

03/24/26

Daiwa Reaffirms Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

€2.5

Buy

44.58%

Upside

Reiterated

03/24/26

Huatai Securities Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

UBS

Not Ranked

UBS

€2.85

Buy

64.92%

Upside

Reiterated

03/23/26

UBS Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€2.2

Hold

27.25%

Upside

Reiterated

03/23/26

Sinopharm Group Co (SHTDF) Gets a Hold from Goldman Sachs

Unknown Analyst

HSBC

Not Ranked

HSBC

€2→€2.16

Sell

25.13%

Upside

Reiterated

11/10/25

HSBC Keeps Their Sell Rating on Sinopharm Group Co (SHTDF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LGNDLigand Pharma

DNLIDenali Therapeutics

ACHVAchieve Life Sciences

PMNProMIS Neurosciences

CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

X2S Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, X2S has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. X2S average Analyst price target in the past 3 months is 2.42.

Each month's total comprises the sum of three months' worth of ratings.

X2S Financial Forecast

X2S Earnings Forecast

The previous quarter’s earnings for X2S were €0.08.

X2S Sales Forecast

The previous quarter’s earnings for X2S were €35.35B.

X2S Stock Forecast FAQ

What is DE:X2S’s average 12-month price target, according to analysts?

Based on analyst ratings, Sinopharm Group Co Ltd Class H’s 12-month average price target is 2.42.

What is DE:X2S’s upside potential, based on the analysts’ average price target?

Sinopharm Group Co Ltd Class H has 39.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sinopharm Group Co Ltd Class H a Buy, Sell or Hold?

Sinopharm Group Co Ltd Class H has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sinopharm Group Co Ltd Class H’s share price target?

The average share price target for Sinopharm Group Co Ltd Class H is 2.42. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €2.74 ,and the lowest forecast is €2.26. The average share price target represents 39.89% Increase from the current price of €1.73.

What do analysts say about Sinopharm Group Co Ltd Class H?

Sinopharm Group Co Ltd Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Sinopharm Group Co Ltd Class H?

To buy shares of DE:X2S, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sinopharm Group Co (X2S) Stock Forecast & Price Target

X2S Analyst Ratings

X2S Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

X2S Analyst Recommendation Trends

X2S Financial Forecast

X2S Earnings Forecast

X2S Sales Forecast

X2S Stock Forecast FAQ

Detailed List of Analyst Forecasts